• 15 June 2010
  • News
  • By

33-35-Themis Medicare-Venkateshwara Hatcheries-Vimta Labs

Themis Medicare

CEO Dr Dinesh Patel
Business Manufacturer and marketer of formulations and APIs of synthetic origin
Start-up Year -
Biotech Revenue Rs 90 crore
Address 11/12, Udyog Nagar, SV Road, Goregaon (West), Mumbai-400 104
Tel +91-22-67607080
Fax +91-22-28746621
Website www.themismedicare.com

Themis Medicare achieved  a total turnover of Rs 90 crore for the year ended March 31, 2010  as against Rs. 97.7 crores for the previous corresponding year. Themis Medicare is a joint venture pharmaceutical company, with Gedeon Richter Limited, Hungary. The company in over three decades, has made its presence felt in manufacturing and marketing of formulations and APIs of synthetic and biotech origin. Though their first breakthrough product was Vitamin B12, Themis moved on to manufacture synthetic APIs such as ethambutol hydrochloride, pyrithioxine derivatives, methylcobalamin, propofol and artemisinin derivatives.

Themis Medicare made its presence felt in  the biotech market when in 2004 it merged with Artemis Biotech. Artemis Biotech is involved in biotechnology and fermentation activity. In the same year, Themis had obtained COS for lovastatin and simvastatin which enabled them to sell these statins in Europe. Lovastatin and Simvastatin today hold a significant share of exports of the company.

Venkateshwara Hatcheries

Chair Person Anuradha Desai
Business R&D, production and export of poultry and diagnostics
Start-up Year 1986
Biotech Revenue Rs 90 crore
Address Venkateshwara House, SN 114/A/2, Pune-Sinhagad Rd, Pune-411030
Tel +91-20-24251530
Fax +91-20-24251077
Website www.venkys.com

Venkateshwara Hatcheries, a part of the Pune-based VH group, posted a revenue of Rs 90 crore for the financial year 2009-2010. As the first company to embark on a process of developing the industry on scientific lines, Venkateshwara Hatcheries occupies a special place in the Indian poultry scene. It pioneered the concept of parent franchisee operations, popularized cage farming, and introduced for the first time in India, the concept of inactivated vaccines and combination vaccines.
The company has poultry operations in Maharashtra, Madhya Pradesh and the southern states of India. Included in its portfolio are new technology driven businesses like the egg powder plant in Hyderabad , a 100 percent export oriented unit, and wind energy farms on the outskirts of Coimbatore.

The VH Group is entering Europe with a state-of-the-art poultry vaccine manufacturing facility in Bassecourt, Switzerland. According to B Venkateshwara Rao, Managing Director of the VH Group, if the approval process goes according to company’s plan, the Swiss facility will be operational by the end of 2011, and it will produce poultry vaccines for the European, Asian and other regulated markets.

Vimta Labs
CEO Dr S P Vasireddi
Business Contract research
Start-up Year 1984
Biotech Revenue Rs 88.42 crore
Address 142, IDA, Phase II, Cherlapally, Hyderabad - 500 051
Tel +91-40-2726 4141
Fax +91-40-2726 3657
Website  www.vimta.com

Vimta Labs is one of India’s leading contract research and testing organization. Established in 1984 Vimta has an envious track record of serving several market leaders across the globe. The company reported biotech revenue of Rs 88.42 crore in 2009-20 as against Rs 81.60 crore in 2008-09
The company is a team of  756 professionals comprising 479 scientists in various disciplines such as chemistry, pharma, medicine, microbiology, molecular biology and informatics. The team is slated to double in next three years. The company is a multi-site organization with more than 300,000 sq ft world class laboratory facilities. The technologies deployed at Vimta are current and leading edge, duly validated. The company also provides full range of services to manage clinical studies from study design to  management to pre-approval and post-marketing service.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email